Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25181574 | 0.83 | NR1H2 (0.54) | NR1H2USP2SMN1; SMN2NAMPTHPGD | |
| SCHEMBL15861680 | 0.83 | NR1H2 (0.50) | NR1H2USP2SMN1; SMN2NAMPTHPGD | |
| SCHEMBL2770843 | 0.83 | HPGD (0.53) | USP2SMN1; SMN2HPGDALDH1A1MAPT | |
| SCHEMBL16414679 | 0.81 | NR1H2 (0.46) | NR1H2USP2SMN1; SMN2NAMPTHPGD | |
| SCHEMBL21640265 | 0.81 | NR1H2 (0.54) | NR1H2USP2SMN1; SMN2NAMPTHPGD | |
| Lithium Ion SCHEMBL21063466 | 0.80 | NR1H2 (0.48) | NR1H2USP2SMN1; SMN2NAMPTHPGD | |
| SCHEMBL14303506 | 0.79 | NR1H2 (0.57) | NR1H2USP2SMN1; SMN2NAMPTHPGD | |
| SCHEMBL4184533 | 0.79 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2NAMPTHPGD | |
| SCHEMBL31449563 | 0.79 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2NAMPTHPGD | |
| SCHEMBL25936274 | 0.79 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2NAMPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| EP-3604305-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | RAB10, HDAC10, NEK10 | NR1H2 876/4885USP2 3341/4885SMN1; SMN2 3320/4885 |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | RARA, RAB10, RABL6 | NR1H2 675/4885USP2 3231/4885SMN1; SMN2 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.